BROWSE·page 913 of 1489

Browse EX-10 agreements

17,865 total material contract exhibits.


EXHIBIT 10.16

Freenome, Inc.


Exhibit 10.16

Agreed Form

FREENOME, INC.

2026 EMPLOYEE STOCK PURCHASE PLAN

The purpose of the Freenome, Inc. 2026 Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of Freenome, Inc. (the “Company”) and each Designated Company (as defined in Section 11) with opportunities to purchase shares of Stock (as defined in Section 11).  An aggregate of 2,462,204 shares of Stock have been approved and reserved for this purpose plus, on January 1, 2027 and each January 1 thereafter through January 1, 2036, the number of shares of Stock reserved and available for issuance under the Plan shall be cumulatively increased by the least of (i) 1% of the number of Outstanding Shares on the immediately preceding December 31st, (ii) 1,500,000 shares of Stock, or (iii) such number of shares of Stock as determined by the Administrator.

…

EX-10.16·8-K·CIK 2017526·ACC 0001140361-26-029471·Filed Jul 23, 2026, 21:30 ET

EXHIBIT 10.18

Freenome, Inc.


Exhibit 10.18

FREENOME, INC.

EMPLOYMENT AGREEMENT

This Employment Agreement (the “Agreement”) is entered into as of May 23, 2016, by and between Riley Ennis (the “Executive”) and Freenome, Inc. a Delaware corporation, having its principal place of business at 2875 Michelle Drive, Suite 300, Irvine, California 92606 (the “Company”).

RECITALS

A.        The Company desires the association and services of Executive and his skills, abilities, background and knowledge, and is willing to engage Executive’s services on the terms and conditions set forth in this Agreement.

B.          Executive desires to be in the employ of the Company, and is willing to accept such employment on the terms and conditions set forth in this Agreement.

…

EX-10.18·8-K·CIK 2017526·ACC 0001140361-26-029471·Filed Jul 23, 2026, 21:30 ET

EXHIBIT 10.24

Freenome, Inc.


Exhibit 10.24

FREENOME, INC.

FORM OF INDEMNIFICATION AGREEMENT

This Indemnification Agreement (“Agreement”) is made as of [________________] by and between Freenome, Inc., a Delaware corporation (the “Company”), and [____________] (“Indemnitee”).

RECITALS

WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company;

WHEREAS, in order to induce Indemnitee to [provide] [continue to provide] services to the Company, the Company wishes to provide for the indemnification of, and advancement of expenses to, Indemnitee to the maximum extent permitted by law;

WHEREAS, the Amended and Restated Certificate of Incorporation (as amended and in effect from time to time, the “Charter”) and the Amended and Restated Bylaws (the “Bylaws”) of the Company require indemnification of the officers and directors of the Company, and Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (the “DGCL”);

…

EX-10.24·8-K·CIK 2017526·ACC 0001140361-26-029471·Filed Jul 23, 2026, 21:30 ET

EXHIBIT 10.17

Freenome, Inc.


Exhibit 10.17

Freenome Holdings, Inc.

January 7, 2026

Aaron Elliott

Re:         Amended and Restated Offer of Employment by Freenome Holdings, Inc.

Dear Aaron:

I am very pleased to confirm our offer to you of employment with Freenome Holdings, Inc. (the “Company”). The terms of our offer and the benefits currently provided by the Company are as follows:

1.        Position and Start Date. You are being offered the position of Chief Executive Officer. This is a full-time position based in our Brisbane, California office. Your anticipated start date will be April 1, 2025, unless you would like to start earlier.

2.         Starting Salary. Your starting salary will be $685,000 per year and will be subject to annual review. Your position is classified as exempt from overtime. As an exempt employee, you will be expected to work the Company’s normal business hours as well as additional hours as required by the nature of your work assignments, and you will not be entitled to overtime compensation.

3.           Bonuses.

…

EX-10.17·8-K·CIK 2017526·ACC 0001140361-26-029471·Filed Jul 23, 2026, 21:30 ET

EXHIBIT 10.20

Freenome, Inc.


Exhibit 10.20

259 East Grand Avenue, Unit 3434

South San Francisco, CA 94080

March 22, 2019

Jimmy Lin

Re: Employment Terms

Dear Jimmy Lin:

Freenome Holdings Inc. (“Freenome” or the “Company”) is pleased to offer you the position of Chief Scientific Officer, on the following terms.

You will be responsible for contributing to the operations associated with Freenome’s Research & Development and Computational Research team and will report to Gabriel Otte, Chief Executive Officer. You will work at our facility located in South San Francisco, CA. Of course, Freenome may change your position, duties, and work location from time to time in its discretion.

…

EX-10.20·8-K·CIK 2017526·ACC 0001140361-26-029471·Filed Jul 23, 2026, 21:30 ET

** **

HASHDEX NASDAQ CME CRYPTO INDEX ETF

AUTHORIZED PARTICIPANT AGREEMENT

This Authorized Participant Agreement (the “Agreement”), dated as of the date of the last signature set forth on the signature pages hereto, is entered into by and among Marex Capital Markets Inc. (the “Authorized Participant”), and is further subject to acknowledgement and agreement by Hashdex Nasdaq CME Crypto Index ETF, a Delaware statutory trust (the “Trust”), and Hashdex Asset Management Ltd., an exempted company incorporated with limited liability under the laws of the Cayman Islands, as sponsor of the Trust (the “Sponsor”).

SUMMARY

…

EX-10.2·8-K·CIK 2031069·ACC 0001213900-26-081061·Filed Jul 23, 2026, 19:25 ET

MASTER PURCHASE AND SALE AGREEMENT

FOR DIGITAL ASSETS

** **

This MASTER PURCHASE AND SALE AGREEMENT FOR DIGITAL ASSETS (this “Agreement”), is made and entered into as of this 22 day of July, 2026, by and between JSCT, LLC, a Delaware limited liability company (“Jane Street”) and Hashdex Asset Management Ltd., (“Sponsor”) as agent and not in its individual capacity, on behalf of the applicable entity identified in Exhibit C (each entity a “Counterparty”, and collectively with Jane Street, the “Parties”), severally but not jointly.

The Parties acknowledge and agree that this Agreement references multiple Counterparties but such references are for the administrative convenience of both Jane Street and each Counterparty. As between Jane Street and a Counterparty, this Agreement shall be interpreted to be a separate agreement between Jane Street and such Counterparty and not any other Counterparty or multiple Counterparties.

…

EX-10.3·8-K·CIK 2031069·ACC 0001213900-26-081061·Filed Jul 23, 2026, 19:25 ET

THIRD AMENDMENT TO SPONSOR AGREEMENT

THIS THIRD AMENDMENT (this “Third Amendment”) to the Sponsor Agreement, dated as of January 27, 2025, as amended by the First Amendment to Sponsor Agreement, dated as of November 12, 2025 (the “First Amendment”), and the Second Amendment to Sponsor Agreement, dated as of March 13, 2026 (the “Second Amendment”, as so amended, the “Sponsor Agreement”), by and between Hashdex Asset Management Ltd., a Cayman limited company (the “Sponsor”), and Hashdex Nasdaq CME Crypto Index ETF (f.k.a. Hashdex Nasdaq Crypto Index US ETF), a statutory trust organized under the laws of Delaware (the “Trust”), is made as of July 23, 2026 (the “Effective Date”) by and between the Sponsor and the Trust.

WHEREAS, reference is made to the Sponsor Agreement; and

…

EX-10.1·8-K·CIK 2031069·ACC 0001213900-26-081061·Filed Jul 23, 2026, 19:25 ET

EX-10.1

INTEL CORP

INTEL CORPORATION

2006 EQUITY INCENTIVE PLAN

AS AMENDED AND RESTATED EFFECTIVE MAY 13, 2026

1. PURPOSE

The purpose of this Intel Corporation 2006 Equity Incentive Plan (the “Plan”) is to advance the interests of Intel Corporation, a Delaware corporation, and its Subsidiaries (hereinafter collectively “Intel” or the “Corporation”), by stimulating the efforts of employees, Outside Directors, and Consultants who are selected to be participants on behalf of Intel, aligning the long-term interests of participants with those of stockholders, heightening the desire of participants to continue in working toward and contributing to the success of Intel, assisting Intel in competing effectively with other enterprises for the services of new employees, Outside Directors, and Consultants necessary for the continued improvement of operations, and to attract, motivate and retain the best available individuals for service to the Corporation. This Plan permits the grant of stock options, stock appreciation rights, restricted stock and restricted stock units, each of which shall be subject to su

…

EX-10.1·10-Q·CIK 50863·ACC 0000050863-26-000157·Filed Jul 23, 2026, 18:44 ET

EX-10.2

INTEL CORP

INTEL CORPORATION

2006 EMPLOYEE STOCK PURCHASE PLAN

AS AMENDED AND RESTATED EFFECTIVE MAY 13, 2026

Section 1.    PURPOSE

The purpose of the Plan is to provide an opportunity for Employees of Intel Corporation, a Delaware corporation (“Intel”) and its Participating Subsidiaries (collectively Intel and its Participating Subsidiaries shall be referred to as the “Company”), to purchase Common Stock of Intel and thereby to have an additional incentive to contribute to the prosperity of the Company. It is the intention of the Company that the Plan (excluding any sub-plans thereof except as expressly provided in the terms of such sub-plan) qualify as an “Employee Stock Purchase Plan” under Section 423 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”), and the Plan shall be administered in accordance with this intent. In addition, the Plan authorizes the grant of options pursuant to sub-plans or special rules adopted by the Committee designed to achieve desired tax or other objectives in particular locations outside of the United States or to achieve other business objec

…

EX-10.2·10-Q·CIK 50863·ACC 0000050863-26-000157·Filed Jul 23, 2026, 18:44 ET

FORM OF PARENT VOTING AND SUPPORT DEED

Neuphoria Therapeutics Inc.

** **

PARENT VOTING AND Support DEED

THIS PARENT VOTING AND SUPPORT DEED (this “Deed”) is made and entered into as of 23 July 2026, by and among Scancell Holdings plc, a public limited company incorporated under the laws of England and Wales (“Parent”), Scancell Merger Sub, Inc., a Delaware corporation and an indirect wholly owned Subsidiary of Parent (“Merger Sub”), Neuphoria Therapeutics Inc., a Delaware corporation (the “Company”) and the shareholder(s) of Parent listed on Schedule A hereto (“Securityholder”). Capitalized terms used but not defined herein are used as they are defined in the Merger Agreement (as defined below).

RECITALS:

…

EX-10.2·DEFA14A·CIK 1191070·ACC 0001213900-26-081054·Filed Jul 23, 2026, 18:39 ET

Agreed Form

FORM OF CONTINGENT VALUE RIGHTS AGREEMENT

** **

**This Contingent Value Rights Agreement **(this “Agreement”), dated as of [●] (the “Effective Date”), is entered into by and between Scancell Holdings plc, a public limited company incorporated in England and Wales under company number 06564638 with its registered office at Bellhouse Building, Sanders Road, Oxford Science Park, Oxford OX4 4GD, United Kingdom (“Parent”), and [●], a [●], as Rights Agent (as defined herein).

** **

RECITALS

** **

…

EX-10.4·DEFA14A·CIK 1191070·ACC 0001213900-26-081054·Filed Jul 23, 2026, 18:39 ET